Ligand News and Research

RSS
Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Research on immune system can develop new therapy for inflammation, tumors

Research on immune system can develop new therapy for inflammation, tumors

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

OpenEye releases Docking TK software to develop new docking tools

OpenEye releases Docking TK software to develop new docking tools

OpenEye Scientific Software releases SZYBKI 1.5.0 optimization application for molecular structures

OpenEye Scientific Software releases SZYBKI 1.5.0 optimization application for molecular structures

BAC, Octapharma enter licence agreement for G-CSF CaptureSelect custom affinity ligand

BAC, Octapharma enter licence agreement for G-CSF CaptureSelect custom affinity ligand

Researchers find link between chronic inflammation and cancer

Researchers find link between chronic inflammation and cancer

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

Ohio State University procures IonFlux 16 high throughput automated patch clamp instrument

Ohio State University procures IonFlux 16 high throughput automated patch clamp instrument

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Ligand second-quarter net loss reduces to $0.3 million

Ligand second-quarter net loss reduces to $0.3 million

Amplimmune collaborates with GSK to develop PD-1 targeting therapies

Amplimmune collaborates with GSK to develop PD-1 targeting therapies

Scientists discover technique for more controlled lab experiments on cellular mechanobiology

Scientists discover technique for more controlled lab experiments on cellular mechanobiology

CD74 can serve as prognostic marker for colorectal cancer

CD74 can serve as prognostic marker for colorectal cancer

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

New mechanism that drives development of B-lymphocytes in bone marrow discovered

New mechanism that drives development of B-lymphocytes in bone marrow discovered

Amgen granted FDA priority review designation for denosumab BLA

Amgen granted FDA priority review designation for denosumab BLA

Ligand Pharmaceuticals announces launch of redesigned Web site

Ligand Pharmaceuticals announces launch of redesigned Web site

Trevena completes $35M Series B financing

Trevena completes $35M Series B financing